Business Wire

Thales Expands Technology Partner Ecosystem to Accelerate Enterprises’ Cloud and Digital Transformation Initiatives

12.8.2020 11:00:00 EEST | Business Wire | Press release

Share

Enterprises can now reduce cyber risk and secure their digital transformation initiatives in new markets including Blockchain, Cloud, DevOps, IoT and Code Signing as Thales unveils an expansion of its data protection ecosystem to more than 300 technology partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005038/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo : Thales)

Through these expanded technology integrations, which now include more than 500 IT products and services, Thales is enabling more organisations to integrate its data encryption, hardware security modules, key management and access management technologies with their existing IT infrastructure and cloud services to protect applications, data and identities. This will empower organisations to implement centralised data protection and access management controls for the whole customer journey.

“The use of the cloud and digital transformation is now the cornerstone of any modern company,” said Sebastien Cano, Senior Vice President for Cloud Protection and Licensing Activities at Thales. “Vitally though, those that are truly leading the way are doing so by integrating security by design into their processes from the start. By integrating our data protection products and services with hundreds of technology partners, we can ensure customers and their sensitive data are protected throughout their entire transformation journey and remain at the forefront of their industries.”

Protecting Blockchain

Thales is collaborating with leading companies that are driving the adoption of Blockchain technology by integrating its Luna Network Hardware Security Modules (HSM) as the root of trust to secure blockchain-based transactions. Recently, Thales integrated its Luna Network HSM with CLS Group – a dedicated crypto processor that is specifically designed for the protection of the crypto key lifecycle – and Hyperledger – a multi-project open source collaborative effort hosted by The Linux Foundation, created to advance cross-industry blockchain technologies.

Enabling Secure Cloud Transformation

Today, organisations on average use 29 cloud services for their collaboration, computing, customer relationship management and storage needs. Thales is helping companies secure the move to the cloud with cloud key management and access management solutions that integrate with the most widely used cloud platforms and services including AWS, Azure, Box, Office365 and Slack.

Thales’s SafeNet Trusted Access enables organisations to modernise their IT and Identity and Access Management (IAM) schemes, as part of their cloud transformation initiatives. For example, integrations with IGA vendors such as SailPoint enable secure identity governance and identity management workflows; Security for privileged users is achieved by securing PAM solutions such as BeyondTrust, at the access point; and continuous authentication and access control is enabled by working with CipherCloud’s CASB solution.

Securing Hybrid IT Environments

While organisations are rapidly adopting cloud services and moving infrastructure to the cloud, the majority are maintaining hybrid IT environments. One of the key challenges they face in doing so is bridging between modern and cloud IAM schemes. To this end, SafeNet Trusted Access’s integration with F5 BIG IP enables enterprises to implement smart SSO for cloud services while securing on premises legacy applications.

“Data and applications are fast becoming the lifeblood of any organisation, no matter the industry,” said John Morgan, VP & GM Security at F5. “For any customer to truly take advantage of this digital transformation, applications and their underlying data must be secure. By joining the Thales partner ecosystem, we are continuing our long history of collaboration to help customers achieve positive business outcomes through secure digital transformation.”

Enabling Trust for DevOps

Digital certificates play an integral role in DevOps workflows, securing authentication across users, devices and applications. The secure identities and certificates establish trust within enterprise infrastructure, pipeline, code and containers. Thales has expanded its DevOps technology partners to include Red Hat, HashiCorp, Kubernetes, VMWare Tanzu, Docker and Google for secure DevOps to enable customers to realise the benefits of automation, scale, & cloud native applications and digital transformation.

Securing the Identities and Data in IoT

In order to secure, manage and authenticate the billions of identities that will be created with the Internet of Things, Thales has recently expanded integrations for its HSMs, Data Encryption and Key Management solutions with leading providers of IoT security solutions such as Cisco, Microsoft, DigiCert, Sectigo, GlobalSign, KeyFactor and Venafi to help organisations secure the billions of identities that will be created over the next few years.

Code Signing becomes an essential service for businesses

Code signing has emerged as an essential ingredient to doing business for virtually any organisation that distributes code to customers and partners. Code signing verifies who the publisher of a specific set of code is and attests that it has not been modified since it was signed. Certificates delivered along with software that has been signed are a key way for users to determine whether software originates from a legitimate source before installing. Today, many software marketplaces, including mobile app stores, require code to be compliant with specific digital signing requirements.

One of those mandates is for applicants to generate and store their private key using a FIPS 140-2 Level 2 certified hardware solution. This can be a Hardware Security Module (HSM) that protects the identity, whether it is the server, virtualization server or the user. Thales' HSMs take the security one step further by storing the signing material in a hardware device, thus ensuring authenticity and integrity of a code file. Thales code signing partners include Adobe, DigiCert, Garantir GlobalSign, Keyfactor, Microsoft and Venafi.

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT
Thales Group
Market page

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS

Thales, Media Relations
Constance Arnoux
+33 (0)6 44 12 16 35
constance.arnoux@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye